Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Autologous peripheral blood stem cell transplantation using Thiotepa, Carboplatin and Etoposide conditioning in patients with relapsed or refractory Medulloblastoma, Primitive neuroectodermal tumor (PNET) and Atypical teratoma and rhabdoid tumor (ATRT)

Trial Profile

Autologous peripheral blood stem cell transplantation using Thiotepa, Carboplatin and Etoposide conditioning in patients with relapsed or refractory Medulloblastoma, Primitive neuroectodermal tumor (PNET) and Atypical teratoma and rhabdoid tumor (ATRT)

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 20 Feb 2019

At a glance

  • Drugs Carboplatin (Primary) ; Etoposide (Primary) ; Thiotepa (Primary)
  • Indications Medulloblastoma; Neuroectodermal tumours; Rhabdoid tumour; Teratoma
  • Focus Adverse reactions
  • Most Recent Events

    • 18 Aug 2017 Status changed from recruiting to active, no longer recruiting.
    • 23 May 2017 Status changed from not yet recruiting to recruiting.
    • 02 May 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top